Did you know that according to the American Cancer Society (ACS), there will be an estimated 2,114,850 new cancer cases and 626,140 cancer deaths in 2026? This means millions of patients will be seeking oncology treatment.
This creates significant operational and financial pressure for oncology revenue cycle management (RCM) teams. Oncology billing involves several challenges, such as:
- Multi-provider treatment plans
- Six-figure drug claims
- Payers that change coverage policies
When it comes to oncology RCM, small gaps in processes can result in significant revenue leakage. A missed authorization, coding error, or delayed follow-up erodes collections required to keep services and treatment programs running.
This is why oncology RCM is no longer just a back-office function but a strategic priority. If healthcare providers manage it well, it:
- Reduces denials
- Protects cash flow
- Provides clinical teams with financial stability
- Increases focus on patient treatment instead of claim management
Why Does Oncology Revenue Cycle Management Matter?
Traditional medical billing workflows were not designed for the complexity of oncology care. Oncology RCM is unique because it may involve charging for:
- High-cost chemotherapy
- Immunotherapy drugs
- Long-term treatment plans
- Coordinating the care of multiple providers (such as radiation oncologists, medical oncologists, surgeons, and infusion nurses)
Overall, billing oncology services under one episode of care can be a fairly complex challenge. That complexity increases significantly without an efficient RCM process.
Oncology revenue cycle management is challenging due to several factors. However, the financial burden alone accounts for a large portion of this challenge.
According to ScienceDirect’s study published in 2026, patients with stage IV cancer incur 60%-80% higher treatment costs compared to early-stage patients.
Moreover, typically oncology practices operate on a buy-and-bill model. This means the practice purchases expensive drugs upfront.
However, the practices receive reimbursements only after treatment is provided and a claim is accepted.
Conversely, a denied claim or reimbursement shortfall can leave the practice absorbing a portion of the treatment cost.
Even a single unpaid infusion can cost tens of thousands of dollars, straining the practice’s revenue. Similarly, repeated prior authorization denials for high-cost therapies can result in the loss of hundreds of thousands of dollars in annual revenue.
Multiplying this potential risk across an active patient panel, it’s clear that practices require an RCM workflow designed specifically for oncology care. A one-size-fits-all billing system isn’t practical for oncology care.
Oncology Billing Rules & Payer Guidelines
Ensuring compliant oncology RCM and billing involves tracking constantly evolving payer-specific rules, and even a single error can delay payment for weeks. Practices may need to monitor the following oncology billing areas carefully:
Prior Authorization (PA) Requirements
PA is regarded as the single biggest driver of oncology billing denials in 2026. Many high-cost oncology services require prior authorization for coverage and reimbursement. Interestingly, regulatory pressure is mounting to rectify this bottleneck.
A rule proposed by CMS would require the following payers to implement electronic PA for prescription drugs covered as of October 1, 2026.
- Medicare Advantage
- Medicaid
- CHIP
- Marketplace plans
However, until this rule is fully implemented, practices should maintain a robust process for tracking internal prior authorization.
Medical Necessity Documentation
Clear documentation supporting medical necessity is essential for accurate oncology billing and reimbursement. Additionally, the documentation must support the patient’s:
- Staging
- Diagnosis
- Treatment guidelines
If documentation is incomplete or insufficient, it might compromise the oncology RCM before the practice realizes it. It is one of the fastest methods to trigger a drawn-out appeal or a denial.
Buy-and-Bill Reimbursement
Under the buy-and-bill model, oncology practices purchase medications, administer them to patients, and then bill the payer for reimbursement.
Therefore, maintaining accuracy on J-codes, National Drug Code (NDC) numbers, and administered units is non-negotiable.
A discrepancy between the administered service and the billed documentation may result in:
- Claim denials
- Payment delays
- Audit scrutiny
Payer-Specific Coverage Policies
Coverage for the same oncology drug may differ among commercial insurers, Medicare Advantage plans, and Medicaid programs.
More importantly, their policies are updated regularly. If the billing staff does not track these changes and submits an incorrect claim, they will face a denial.
Even a single denial or payment delay can negatively affect oncology RCM. So a service covered under medical benefit in the last quarter may become a pharmacy benefit this quarter. Thus, billing teams must carefully monitor each move.
Drug Waste and Reimbursement Policies
Proper billing of discarded drug amounts can be challenging for newer oncology practices. It requires using appropriate modifiers (like JW and JZ modifiers), and failing to bill discarded drugs correctly may result in:
- Incorrect billing
- Claim denials
- Audit scrutiny
Timely Filing Requirements
When it comes to oncology RCM, the filing requirements are a crucial detail that must be considered. However, oncology care often involves extended treatment courses, causing oncology practices to lose track.
The challenge becomes even greater when multiple prior authorizations and filing deadlines must be managed simultaneously.
Coordination of Benefits (COB)
According to the Kaiser Family Foundation (KFF), approximately 12 million people are enrolled in both Medicare and Medicaid. Many oncology patients fall into these coverage categories and may have:
- Secondary insurance
- Medicare supplements
- Dual coverage
Such patients require accurate COB to prevent improper billing and errors. However, not all billing teams fully understand COB requirements. This results in major disruptions in oncology RCM and requires immediate attention.
Ongoing Policy Updates
Governing bodies are consistently streamlining and standardizing billing practices. This often leads to ongoing policy updates, which may increase the risk of revenue loss if practices fail to remain compliant.
A practice in charge of its oncology RCM must stay informed of changes and make necessary operational or billing adjustments in its systems.
Interestingly, state-level legislative activity also has a direct impact on these policies. For instance, the American Society of Clinical Oncologists (ASCO)’s state bill tracker provides important insights.
It indicates that lawmakers have introduced prior authorization reform bills in 2026 alone. This has been happening across 42 states, and several have already been signed into law.
These changes can directly affect reimbursement workflows, prior authorization processes, and billing operations. Practices should also stay current with annual CPT coding updates to ensure compliant oncology billing.
Appeals and Denial Policies
Denial management in oncology billing isn’t a one-size-fits-all template. Each payer may have its own:
- Appeal timeline
- Documentation format
- Escalation path
Violating any of these requirements can lead to a permanent denial. When appropriate, practices may need peer-to-peer clinical review as part of the appeal process for medical necessity or prior authorization denials.
If you are serious about oncology revenue cycle management, you need to learn about the latest Oncology CPT Codes in 2026.
Key Reasons for Revenue Leakage in Oncology Practice
Revenue leakage is one of the biggest threats to an effective oncology RCM. Most leakages go unnoticed for long durations, damaging the practice’s finances. Notably, revenue leakage is typically not due to a single dramatic failure.
Instead, revenue leakage often results from multiple small failures that compound over time. According to the Association of Cancer Care Centers (ACCC), the most common culprits are:
Missed or Expired Authorizations
Prior authorization challenges remain one of the leading causes of revenue leakage in oncology practices. However, other contributors can also increase the difficulty, including:
- Changes in treatment plans
- Adjustments in drug dosages
- Authorization updates mid-treatment
Unless oncology practices establish a system for tracking expiration dates, the risk of denials and reimbursement delays will continue to increase. Apart from oncology RCM challenges, the quality of care may also suffer.
Untimely Follow-Up
All medical claims are time-sensitive, and claims sitting in accounts receivable without active follow-up are at a higher risk. Recovery becomes less likely as claims continue to age.
As a general rule of thumb, the longer a claim ages, the lower the chances a practice has of a full recovery. Therefore, practices must prioritize pending claims to streamline oncology RCM.
Charge Capture Gaps
Practices cannot expect appropriate reimbursement if services are not captured accurately. Charge capture is the foundation of any oncology RCM.
Services rendered but lacking documentation or coding do not get billed. This often becomes a cause of revenue loss that might remain unseen until it becomes serious.
Slow Payment Posting
Delayed payment posting slows reconciliation of payer payments and delays the identification of:
- Denials
- Underpayments
- Payment variances
Therefore, posted payments may require contractual adjustments or reconciliation, which may prolong the billing timeline. From a billing perspective, oncology practices may find it more challenging to identify denials or underpayments, extending the appeals timeline.
Underpaid Claims
Contracted reimbursement rates establish the expected payment amounts. However, payers may not reimburse services at the contracted rate.
Therefore, oncology practices must audit all payments against fee schedules. Without routine payment audits, underpayments may remain undetected for long durations.
Drug Reimbursement Discrepancies
Not all oncology RCM disruptions are external. Sometimes, an in-house billing team may not be equipped to manage operations. Therefore, internal billing errors may occur in:
- Waste documentation
- NDC reporting
- Unit calculations
These errors can impact the final payments of an oncology claim, reducing or delaying reimbursement for high-cost oncology drugs.
That said, revenue leakage and oncology RCM disruptions may be caused by multiple reasons. However, addressing these challenges is imperative for practices that prioritize a smooth revenue cycle.
Best Practices to Improve Oncology RCM Performance
Improving oncology RCM performance requires strict operational discipline throughout the revenue cycle. Therefore, fixing coding errors after they arise is insufficient.
The following are a few strategies that ensure your oncology RCM performance improves:
- Verify treatment requirements, insurance benefits, and coverage rules before services begin to avoid claim denials.
- Use data-driven appeals and conduct timely denial analysis to achieve a higher acceptance rate of claims.
- Track prior authorizations, patient information, and expiration dates in a centralized system to avoid treatment delays.
- Optimize clinical and billing team coordination for improved documentation quality and fewer claim errors.
- Track and monitor key performance metrics, such as clean claim rates, denial rates, and accounts receivable days, to reveal revenue risks early.
- Implement oncology-specific billing automation for quickly accepted claims and reduced human errors.
- Audit drug billing, NDC codes, units, and waste documentation regularly to ensure accurate reimbursement.
- Adopt a proactive revenue cycle approach to resolve issues early and minimize revenue loss.
Adopting the above-mentioned practices ensures your oncology revenue cycle management is streamlined. However, incorporating these best practices requires the right team.
How Outsourcing Oncology RCM Helps Practitioners
Oncology billing has become increasingly complex, and managing every aspect in-house is no longer the most practical option. A specialized billing team understands the unique reimbursement requirements for oncology revenue cycle management.
The right billing team should understand:
- Infusion service billing
- Prior authorization workflows
- Payer-specific oncology coverage policies
- High-cost drug reimbursement rules
Effective oncology RCM requires far more than administrative support. Therefore, oncology practices, hospitals, and cancer centers seeking fewer denials, higher collections, and maximized revenue performance should consider their options.
Partner with MediBillMD for expert oncology billing services and witness reduced denials, improved collections, and enhanced financial health for your practice in 2026 and beyond.
